Effect of multiple-dose regimens of cyclooxygenase inhibitors and their combinations with mexidol on behavior in mature rats ; Влияние ингибиторов циклооксигеназы и их комбинаций с мексидолом при курсовом применении на поведение половозрелых крыс

Συγγραφείς: E. A. Ivanova, A. G. Vasilchuk, A. I. Matyushkin, T. A. Voronina, Е. А. Иванова, А. Г. Васильчук, А. И. Матюшкин, Т. А. Воронина

Πηγή: Pharmacokinetics and Pharmacodynamics; № 1 (2023); 33-40 ; Фармакокинетика и Фармакодинамика; № 1 (2023); 33-40 ; 2686-8830 ; 2587-7836

Θεματικοί όροι: крысы, diclofenac sodium, etoricoxib, mexidol, open field test, rotarod test, elevated plus maze test, rats, диклофенак натрия, эторикоксиб, мексидол, тест «Открытое поле», тест «Вращающийся стержень», тест «Приподнятый крестообразный лабиринт»

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmacokinetica.ru/jour/article/view/357/326; Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal antiinflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020 Oct;180:114147. DOI:10.1016/j.bcp.2020.114147.; Каратеев А. Е., Насонов Е. Л., Ивашкин В. Т. и др.; Ассоциация ревматологов России, Российское общество по изучению боли, Российская гастроэнтерологическая ассоциация, Российское научное медицинское общество терапевтов, Ассоциация травматологов-ортопедов России, Российская ассоциация паллиативной медицины. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(Прил. 1):1–29. DOI:10.14412/1995-4484-2018-1-29.; Peri KG, Hardy P, Li DY, Varma DR, Chemtob S. Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn. J Biol Chem. 1995 Oct 13;270(41):24615-20. DOI:10.1074/jbc.270.41.24615.; Kaufmann WE, Andreasson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins. 1997 Sep;54(3):601–624. DOI:10.1016/s0090-6980(97)00128-7.; Sayyah M, Boostani H, Pakseresht S, Malayeri A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res. 2011 Oct 30;189(3):403-406. DOI:10.1016/j.psychres.2011.01.019.; Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012 Dec 10;141(2-3): 308–314. DOI:10.1016/j.jad.2012.03.033.; Shalbafan M, Mohammadinejad P, Shariat SV, Alavi K, Zeinoddini A, Salehi M, Askari N, Akhondzadeh S. Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial. Pharmacopsychiatry. 2015 Jul;48(4-5): 136–140. DOI:10.1055/s-0035-1549929.; Hu K, Sjölander A, Lu D, Walker AK, Sloan EK, Fall K, Valdimarsdóttir U, Hall P, Smedby KE, Fang F. Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study. BMC Med. 2020 Sep 9;18(1):238. DOI:10.1186/s12916-020-01709-4.; Kessing LV, Rytgaard HC, Gerds TA, Berk M, Ekstrøm CT, Andersen PK. New drug candidates for depression — a nationwide population-based study. Acta Psychiatr Scand. 2019 Jan;139(1):68–77. DOI:10.1111/acps.12957.; Карева Е.Н., Олейникова О.М., Сереброва С.Ю. и др. Побочные эффекты НПВС и пути их профилактики. Экспериментальная и клиническая фармакология. 2022;85(3):33–44. DOI:10.30906/0869-2092-2022-85-3-33-44.; Napora P, Kobrzycka A, Pierzchała-Koziec K, Wieczorek M. Effect of selective cyclooxygenase inhibitors on animal behaviour and monoaminergic systems of the rat brain. Behav Brain Res. 2023 Feb 13;438:114143. DOI:10.1016/j.bbr.2022.114143.; Иванова Е.А., Матюшкин А.И., Васильчук А.Г., Воронина Т.А. Влияние ингибиторов циклооксигеназы эторикоксиба и диклофенака натрия, а также их комбинаций с мексидолом на поведение крыс. Вестник Московского университета. Серия 16. Биология. 2021;76(3): 148–154. DOI:10.3103/S009639252103007X.; Иванова Е.А., Васильчук А.Г., Матюшкин А.И., Воронина Т.А. Усиление противовоспалительного и анальгетического эффекта диклофенака натрия при его применении в комбинации с мексидолом в эксперименте на грызунах. Экспериментальная и клиническая фармакология. 2020;83(7):22–26. DOI:10.30906/0869-20922020-83-7-22-26.; Иванова Е.А., Матюшкин А.И., Васильчук А.Г., Воронина Т.А. Способность мексидола усиливать антиэкссудативное действие диклофенака натрия и эторикоксиба на модели каррагенанового отека у крыс и мышей. Вестник Московского университета. Серия 16. Биология. 2021;76(2):61–66. DOI:10.3103/S0096392521020024.; Лукьянова Л.Д. Современные проблемы адаптации к гипоксии. Сигнальные механизмы и их роль в системной регуляции. Патологическая физиология и экспериментальная терапия. 2011;(1):3–19.; Лукьянова Л.Д. Сигнальные механизмы гипоксии. Монография. М.: РАН; 2019. С. 214.; Воронина Т.А. Мексидол: Основные нейропсихотропные эффекты и механизм действия. Фарматека. 2009;(6):28–31.; Дюмаев К.М., Воронина Т.А., Смирнов Л.Д. Антиоксиданты в профилактике и терапии патологий ЦНС. – М.: Издательство Института биомедицинской химии; 1995.; Бурлакова Е.Б., Кайране Ч.Б., Молочкина Е.М., и др. Модификация липидов наружной мембраны митохондрий печени мышей и кинетических параметров мембраносвязанной моноаминоксидазы in vivo и in vitro. Вопросы медицинской химии. 1984;30(1):66–72.; Щулькин А.В. Влияние мексидола на развитие феномена эксайтотоксичности нейронов in vitro. Журнал неврологии и психиатрии имени С.С. Корсакова. 2012. Т. 112. № 2. С. 35–39.; Еременко А.В. Роль мембранотропных свойств производных 3-оксипиридина в фармакологическом эффекте. Автореферат к дис. канд. биол. наук. Москва; 1986.; Кирова Ю.И., Шакова Ф.М., Германова Э.Л., Романова Г.А., Воронина Т.А. Влияние Мексидола на церебральный митохондриогенез в молодом возрасте и при старении. Журнал неврологии и психиатрии имени С.С. Корсакова. 2020;120(1):55–62. DOI:10.17116/jnevro202012001155.; Jodeiri Farshbaf M, Kiani-Esfahani A. Succinate dehydrogenase: Prospect for neurodegenerative diseases. Mitochondrion. 2018 Sep;42:77–83. DOI:10.1016/j.mito.2017.12.002.; Uittenbogaard M, Chiaramello A. Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr Pharm Des. 2014;20(35):5574–5593. DOI:10.2174/1381612820666140305224906.; Калинина Т.С., Шимширт А.А., Кудряшов Н.В., и др. Нейростероидогенез и ориентировочно-исследовательское поведение грызунов. Экспериментальная и клиническая фармакология. 2014;77(2):3–7. DOI:10.30906/0869-2092-2014-77-2-3-7.; Воронина Т.А., Середенин С.Б., Яркова М.А., и др. Методические рекомендации по доклиническому изучению транквилизирующего (анксиолитического) действия лекарственных средств. Руководство по проведению доклинических исследованию лекарственных средств. М.: Издательство ФГБУ НЦЭМСП Минздравсоцразвития России; 2012. С. 264–275.; Wright CL, Burks SR, McCarthy MM. Identification of prostaglandin E2 receptors mediating perinatal masculinization of adult sex behavior and neuroanatomical correlates. Dev Neurobiol. 2008 Oct;68(12):1406–1419. DOI:10.1002/dneu.20665.; Lenz KM, Wright CL, Martin RC, McCarthy MM. Prostaglandin E regulates AMPA receptor phosphorylation and promotes membrane insertion in preoptic area neurons and glia during sexual differentiation. PLoS One. 2011 Apr 7;6(4):e18500. DOI:10.1371/journal.pone.0018500.; Kretschmer BD, Goiny M, Herrera-Marschitz M. Effect of intracerebral administration of NMDA and AMPA on dopamine and glutamate release in the ventral pallidum and on motor behavior. J Neurochem. 2000 May;74(5):2049-2057. DOI:10.1046/j.1471-4159.2000.0742049.x.; Васильчук А.Г., Иванова Е.А., Матюшкин А.И., Алексеева С.В., Качалов К.С., Воронина Т.А. Влияние ингибиторов циклооксигеназы эторикоксиба и диклофенака натрия, а также их комбинаций с мексидолом на артериальное давление и гематологические показатели у крыс. Вестник Московского университета. Серия 16. Биология. 2022;77(1):22–28. DOI:10.3103/S0096392522010059.; Liu X, Lee TL, Wong PT. Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135–140. DOI:10.1213/01.ane.0000189102.09347.2e.; https://www.pharmacokinetica.ru/jour/article/view/357

Διαθεσιμότητα: https://www.pharmacokinetica.ru/jour/article/view/357
https://doi.org/10.37489/2587-7836-2023-1-33-40

Results of an open multicenter non-interventional study of clinical efficacy and tolerability of etoricoxib in osteoarthritis and nonspecific back pain with additional evaluation of the effect of the drug on the «central» manifestations of pain ; Результаты открытого многоцентрового неинтервенционного исследования клинической эффективности и переносимости эторикоксиба при остеоартрите и неспецифической боли в спине с дополнительной оценкой влияния препарата на «центральные» проявления боли

Συγγραφείς: A. E. Karateev, E. Yu. Polishchuk, E. S. Filatova, V. N. Amirdzhanova, V. A. Nesterenko, A. S. Potapova, S. I. Glukhova, A. M. Lila, A. V. Sarapulova, A. A. Mukhin, O. S. Lyusina, L. A. Levasheva, E. V. Kryukova, D. K. Klein, N. V. Kichai, M. A. Kabalyk, N. E. Dobrokhotova, Yu. Yu. Grabovetskaya, L. A. Blagodareva, E. V. Zonova, S. M. Zwinger, P. P. Popov, А. Е. Каратеев, Е. Ю. Полищук, Е. С. Филатова, В. Н. Амирджанова, В. А. Нестеренко, А. С. Потапова, С. И. Глухова, А. М. Лила, А. В. Сарапулова, А. А. Мухин, О. С. Люсина, Л. А. Левашева, Е. В. Крюкова, Д. К. Клейн, Н. В. Кичай, М. А. Кабалык, Н. Э. Доброхотова, Ю. Ю. Грабовецкая, Л. А. Благодарева, Е. В. Зонова, С. М. Цвингер, П. П. Попов

Πηγή: Modern Rheumatology Journal; Том 16, № 2 (2022); 34-42 ; Современная ревматология; Том 16, № 2 (2022); 34-42 ; 2310-158X ; 1996-7012

Θεματικοί όροι: эторикоксиб, chronic nonspecific back pain, central sensitization, CSI, etoricoxib, хроническая неспецифическая боль в спине, центральная сенситизация

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1272/1226; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2020. 448 с.; Clauw DJ, Essex MN, Pitman V, Jones KD. Reframing chronic pain as a disease, not a symptom: rationale and implications for pain management. Postgrad Med. 2019 Apr;131(3):185-98. doi:10.1080/00325481.2019.1574403. Epub 2019 Feb 11.; Trouvin AP, Perrot S. Pain in osteoarthritis. Implications for optimal management. Joint Bone Spine. 2018 Jul;85(4):429-34. doi:10.1016/j.jbspin.2017.08.002.; Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018 Jun 9; 391(10137):2356-67. doi:10.1016/S0140-6736(18)30480-X. Epub 2018 Mar 21.; Mathias K, Amarnani A, Pal N, et al. Chronic Pain in Patients with Rheumatoid Arthritis. Curr Pain Headache Rep. 2021 Jul 16;25(9):59. doi:10.1007/s11916-021-00973-0.; Curatolo M, Arendt-Nielsen L. Central hypersensitivity in chronic musculoskeletal pain. Phys Med Rehabil Clin N Am. 2015 May;26(2):175-84. doi:10.1016/j.pmr.2014.12.002.; Arant KR, Katz JN, Neogi T. Quantitative sensory testing: identifying pain characteristics in patients with osteoarthritis. Osteoarthritis Cartilage. 2022 Jan;30(1):17-31. doi:10.1016/j.joca.2021.09.011.; Magni A, Agostoni P, Bonezzi C, et al. Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain Ther. 2021 Dec; 10(2):783-808. doi:10.1007/s40122-021-00260-1.; Takemoto JK, Reynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20. doi:10.2165/00003088-200847110-00002.; Renner B, Zacher J, Buvanendran A, et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Naunyn Schmiedebergs Arch Pharmacol. 2010 Feb;381(2):127-36. doi:10.1007/s00210-009-0482-0. Epub 2010 Jan 6.; Piirainen A, Kokki M, Hautajдrvi H, et al. The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clin Drug Investig. 2016 Jul;36(7):545-55. doi:10.1007/s40261-016-0400-4.; Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi:10.1097/j.pain.0000000000000562.; Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Nov;25(11):1781-91. doi:10.1016/j.joca.2017.07.009. Epub 2017 Aug 2.; https://painrussia.ru/publications/the-questionnaires-and-scales-to-assesspain/csi.default.ivp.php; Gervais-Hupe J, Pollice J, Sadi J, Carlesso LC. Validity of the central sensitization inventory with measures of sensitization in people with knee osteoarthritis. Clin Rheumatol. 2018 Nov;37(11):3125-32. doi:10.1007/s10067-018-4279-8. Epub 2018 Sep 3.; Есин ОР, Горобец ЕА, Хайруллин ИХ и др. Опросник центральной сенситизации — русскоязычная версия. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(6):51-6.; Бахтадзе МА, Чурюканов МВ, Кукушкин МЛ и др. Опросник для оценки центральной сенситизации: лингвистическая адаптация русскоязычной версии. Российский журнал боли. 2020;18(4):40-5.; Sheldon EA, Bird SR, Smugar SS, Tershakovec AM. Correlation of measures of pain, function, and overall response: results pooled from two identical studies of etoricoxib in chronic low back pain. Spine (Phila Pa 1976). 2008 Mar 1;33(5):533-8. doi:10.1097/BRS.0b013e3181657d24.; Da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non-steroidal antiinflammatory drugs and opioid treatment for knee and hip osteoarthritis: network metaanalysis. BMJ. 2021 Oct 12;375:n2321. doi:10.1136/bmj.n2321.; Moore AR, Smugar SS, Wang H, et al. Numbers-needed-to-treat analyses – do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebocontrolled chronic low back pain trials. Pain. 2010 Dec;151(3):592-7. doi:10.1016/j.pain.2010.07.013.; Zolio L, Lim KY, McKenzie JE, et al. Systematic review and meta-analysis of the prevalence of neuropathic-like pain and/or pain sensitization in people with knee and hip osteoarthritis. Osteoarthritis Cartilage. 2021 Aug;29(8):1096-116. doi:10.1016/j.joca.2021.03.021. Epub 2021 May 8.; Schuttert I, Timmerman H, Petersen KK, et al. The Definition, Assessment, and Prevalence of (Human Assumed) Central Sensitisation in Patients with Chronic Low Back Pain: A Systematic Review. J Clin Med. 2021 Dec 17;10(24):5931. doi:10.3390/jcm10245931.; Каратеев АЕ. Эторикоксиб может использоваться при хронической неспецифической боли в спине: новое показание для хорошо известного препарата. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):125-30.; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi:10.1371/journal.pone.0190798. eCollection 2018.; Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006 Oct 4;296(13):1619-32. doi:10.1001/jama.296.13.jrv60015. Epub 2006 Sep 12.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1272
https://doi.org/10.14412/1996-7012-2022-2-34-42

Effect of cyclooxygenase inhibitors etoricoxib and diclofenac sodium as well as their combinations with mexidol on behavior in rats ; Влияние ингибиторов циклооксигеназы эторикоксиба и диклофенака натрия, а также их комбинаций с мексидолом на поведение крыс

Συγγραφείς: E. A. Ivanova, A. I. Matyushkin, A. G. Vasilchuk, T. A. Voronina, Е. А. Иванова, А. И. Матюшкин, А. Г. Васильчук, Т. А. Воронина

Συνεισφορές: Работа выполнена в рамках госзадания по теме № 0521-2019-0007.

Πηγή: Vestnik Moskovskogo universiteta. Seriya 16. Biologiya; Том 76, № 3 (2021); 148-154 ; Вестник Московского университета. Серия 16. Биология; Том 76, № 3 (2021); 148-154 ; 0137-0952

Θεματικοί όροι: крысы, etoricoxib, mexidol, locomotor activity, tail suspension test, rats, эторикоксиб, мексидол, двигательная активность, тест подвешивания за хвост

Περιγραφή αρχείου: application/pdf

Relation: https://vestnik-bio-msu.elpub.ru/jour/article/view/1024/559; Murray C.J.L., Afshin A., Alam T., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 // Global Health Metrics. 2018. Vol. 392. N 10159. P. 1789–1858.; Michopoulos V., Powers A., Gillespie C.F., Ressler K.J., Jovanovic T. Inflammation in fear- and anxietybased disorders: PTSD, GAD, and Beyond // Neuropsychopharmacol. 2017. Vol. 42. N 1. P. 254–270.; Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs // New Engl. J. Med. 2005. Vol. 353. N 16. P. 1711–1723.; Bierhaus A., Wolf J., Andrassy M., et al. A mechanism converting psychosocial stress into mononuclear cell activation // Proc. Natl. Acad. Sci. U.S.A. 2003. Vol. 100. N 4. Р. 1920–1925.; Merkulov V.M., Merkulova T.I., Bondar N.P. Mechanisms of brain glucocorticoid resistance in stressinduced psychopathologies // Biochemistry. 2017. Vol. 82. N 3. P. 351–365.; Raison C.L., Lowry C.A., Rook G.A. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression // Arch. Gen. Psychiat. 2010. Vol. 67. N 12. P. 1211–1224.; Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., Heim C.M. Increased stressinduced inflammatory responses in male patients with major depression and increased early life stress // Am. J. Psychiat. 2006. Vol. 163. N 9. P. 1630–1633.; Portanova J.P., Zhang Y., Anderson G.D., Hauser S.D., Masferrer J.L., Seibert K., Gregory S.A., Isakson P.C. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin-6 production in vivo // J. Exp. Med. 1996. Vol. 184. N 3. P. 883–891.; Nishino S., Ueno R., Ohishi K., Sakai T., Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression // Am. J. Psychiat. 1989. Vol. 146. N 3. P. 365–368.; Ohishi K., Ueno R., Nishino S., Sakai T., Hayaishi O. Increased level of salivary prostaglandins in patients with major depression // Biol. Psychiat. 1988. Vol. 23. N 4. P. 326–334.; Wang J., Dunn A.J. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism // Neurochem. Int. 1998. Vol. 33. N 2. P. 143–154.; Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., Mohebbi-Rasa S., Raznahan M., Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial // Depress. Anxiety. 2009. Vol. 26. N 7. P. 607–611.; Müller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Müller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Möller H-J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine // Mol. Psychiatr. 2006. Vol. 11. N 7. P. 680–684.; Rapoport S.I. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease // Prostag. Leukotr. Ess. 2008. Vol. 79. N 3–5. P. 153–156.; Hu K., Sjölander A., Lu D., Walker A.K., Sloan E.K., Fall K., Valdimarsdóttir U., Hall P., Smedby K.E., Fang F. Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study // BMC Med. 2020. Vol. 18. N 1: 238.; Voronina T.A., Seredenin S.B. Analysis of the mechanism of psychotropic action of 3-hydroxypyridine derivative // Ann. I. Super. Sanita. 1988. Vol. 24. N 3. P. 461–466.; Воронина Т.А. Мексидол: основные нейропсихотропные эффекты и механизм действия // Фарматека. 2009. Т. 180. № 6. С. 28–31.; Ivanova E.A., Matyushkin A.I., Vasilchuk A.G., Voronina T.A. Ability of mexidol to enhance antiexudative effect of diclofenac sodium and etoricoxib in rats and mice with carrageenan-induced edema // Moscow Univ. Biol. Sci. Bull. 2021. Vol. 76. N 2. P. 46–51.; Воронина Т.А., Середенин С.Б., Яркова М.А., Воронин М.В. Методические рекомендации по доклиническому изучению транквилизирующего (анксиолитического) действия лекарственных средств // Руководство по проведению доклинических исследованию лекарственных средств / Под ред. А.Н. Миронова, Н.Д. Бунятян, А.Н. Васильева и др. М.: Изд-во ФГБУ НЦЭМСП Минздравсоцразвития России, 2012. С. 264–275.; Chermat R., Thierry B., Mico J.-A., Stéru L., Simon P. Adaptation of the tail suspension test to the rat // J. Pharmacol. 1986. Vol. 17. N 3. P. 348–350.; Шимширт А.А., Калинина Т.С., Воронина Т.А. Изучение влияния диазепама на тревожные реакции у мышей, вызванные индометацином // Рос. биотер. журн. 2012. Т. 11. № 1. С. 45–46.; Guo J.Y., Li C.-Y., Ruan Y.-P., Sun M., Qi X.-L., Zhao B.-S., Luo F. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressivelike behavior via reducing cyclooxygenase-2 expression in rat brain // Eur. J. Pharmacol. 2009. Vol. 612. N 1–3. P. 54–60.; Kessing L.V., Rytgaard H.C., Gerds T.A., Berk M., Ekstrøm C.T., Andersen P.K. Newdrug candidates for depression – a nationwide population-based study // Acta Psychiat. Scand. 2019. Vol. 139. N 1. P. 68–77.; Wium-Andersen I.K., Wium-Andersen M.K., Jørgensen M.B., Osler M. Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147487 Danish patients // J Psychiatr. Neurosci. 2017. Vol. 42. N 5. P. 320–330.; Aid S., Langenbach R., Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase2 // J. Neuroinflamm. 2008. Vol. 5: 17.

Διαθεσιμότητα: https://vestnik-bio-msu.elpub.ru/jour/article/view/1024

Ability of mexidol to enhance antiexudative effect of diclofenac sodium and etoricoxib in rats and mice with carrageenan-induced edema ; Способность мексидола усиливать антиэкссудативное действие диклофенака натрия и эторикоксиба на модели каррагенанового отека у крыс и мышей

Συγγραφείς: E. A. Ivanova, A. I. Matyushkin, A. G. Vasilchuk, T. A. Voronina, Е. А. Иванова, А. И. Матюшкин, А. Г. Васильчук, Т. А. Воронина

Συνεισφορές: This study was performed under the state assignment of Zakusov Institute of Pharmacology, project number 0521-2019-0007., Работа выполнена в рамках Госзадания по теме № 0521-2019-0007.

Πηγή: Vestnik Moskovskogo universiteta. Seriya 16. Biologiya; Том 76, № 2 (2021); 61-66 ; Вестник Московского университета. Серия 16. Биология; Том 76, № 2 (2021); 61-66 ; 0137-0952

Θεματικοί όροι: мыши, diclofenac sodium, etoricoxib, exudative inflammation, carrageenan-induced edema, rats, mice, диклофенак натрия, эторикоксиб, экссудативное воспаление, каррагенановый отек, крысы

Περιγραφή αρχείου: application/pdf

Relation: https://vestnik-bio-msu.elpub.ru/jour/article/view/992/548; Chang M.-K., Binder C.J., Miller Y.I., Subbanagounder G., Silverman G.J., Berliner J.A., Witztum J.L. Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory // J. Exp. Med. 2004. Vol. 200. N 11. P. 1359–1370.; Chou M.-Y., Hartvigsen K., Hansen L.F., Fogelstrand L., Shaw P.X., Boullier A., Binder C.J., Witztum J.L. Oxidationspecific epitopes are important targets of innate immunity // J. Intern. Med. 2008. Vol. 263. N 5. P. 479–488.; Leslie C.C. Cytosolic phospholipase A2: physiological function and role in disease // J. Lipid. Res. 2015. Vol. 56. N 8. P. 1386–1402.; Calder P.C. Eicosanoids // Essays Biochem. 2020. Vol. 64. N 3. P. 423–441.; Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase // Proc. Natl. Acad. Sci. U.S.A. 1994. Vol. 90. N 24. P. 11693–11697.; Ricciotti E., Fitzgerald G.A. Prostaglandins and inflammation // Arterioscler. Thromb. Vasc. Biol. 2011. Vol. 31. N 5. P. 986–1000.; McAdam B.F., Mardini I.A., Habib A., Burke A., Lawson J.A., Kapoor S., FitzGerald G.A. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation // J. Clin. Invest. 2000. Vol. 105. N 10. P. 1473–1482.; Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease // J. Lipid Res. 2009. Vol. 50 (Suppl). P. S423–S428.; Crofford L.J., Wilder R.L., Ristimaki A.P., Sano H., Remmers E.F., Epps H.R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin- 1 beta, phorbol ester, and corticosteroids // J. Clin. Invest. 1994. Vol. 93. N 3. P. 1095–1101.; Schonbeck U., Sukhova G.K., Graber P., Coulter S., Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions // Am. J. Pathol. 1999. Vol. 155. N 4. P. 1281–1291.; Mardini I.A., FitzGerald G.A. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs // Mol. Interv. 2001. Vol. 1. N 1. P. 30–38.; Воронина Т.А. Мексидол: основные нейропсихотропные эффекты и механизм действия // Фарматека. 2009. Т. 180. № 6. С. 1–4.; Rafiee L., Hajhashemi V., Javanmard S.H. Maprotiline inhibits COX2 and iNOS gene expression in lipopolysaccharide-stimulated U937 macrophages and carrageenan-induced paw edema in rats // Cent. Eur. J. Immunol. 2019. Vol. 44. N 1. P. 15–22.; Kuedo Z., Sangsuriyawong A., Klaypradit W., Tipmanee V., Chonpathompikunlert P. Effects of Astaxanthin from Litopenaeus Vannamei on carrageenaninduced edema and pain behavior in mice // Molecules. 2016. Vol. 21. N 3: 382.; Abd-Allah A.A.M., El-Deen N.A.M.N., Mohamed W.A.M., Naguib F.M. Mast cells and proinflammatory cytokines roles in assessment of grape seeds extract anti-inflammatory activity in rat model of carrageenan-induced paw edema // Iran. J. Basic. Med. Sci. 2018. Vol. 21. N 1. P. 97–107.; Mitrea D.R., Malkey R., Florian T.L., Filip A., Clichici S., Bidian C., Moldovan R., Hoteiuc O.A., Toader A.M., Baldea I. Daily oral administration of chlorogenic acid prevents the experimental carrageenan-induce d oxidative stress // J. Physiol. Pharmacol. 2020. Vol. 71. N 1. P. 55–65.; Winter C.A., Risley E.A., Nuss G.W. Carrageenininduced edema in hind paw of the rat as an assay for antiiflammatory drugs // Proc. Soc. Exp. Biol. Med. 1962. Vol. 111. P. 544–547.; Иванова Е.А., Васильчук А.Г., Матюшкин А.И., Воронина Т.А. Усиление противовоспалительного и анальгетического эффекта диклофенака натрия при его применении в комбинации с мексидолом в эксперименте на грызунах // Эксперим. клин. фармакол. 2020. Т. 83. № 8. С. 38–42.; Хазанов В.А. Фармацевтические композиции на основе нестероидных противовоспалительных средств. Патент на изобретение RU 2191582, Бюлл. № 30. 2002.; Новиков В.Е., Илюхин С.А. Влияние гипоксена на эффективность кислоты ацетилсалициловой при остром воспалении // Эксперим. клин. фармакол. 2013. Т. 76. № 4. С. 32–35.; Smirnov L.D., Voronina T.A., Dyumaev K.M. Effect of a 3-hydroxypyridine derivative membrane modulator on pharmacological activity of some psychotropic drugs // Bull. Exp. Biol. Med. 1985. Vol. 99. N 5. P. 537–540.

Διαθεσιμότητα: https://vestnik-bio-msu.elpub.ru/jour/article/view/992

Pharmacoeconomic analysis of Movalis in patients with osteoarthritis and rheumatoid arthritis

Συγγραφείς: E. S. Tsvetkova, D. Yu. Belousov, E. V. Afanasyeva

Πηγή: Качественная клиническая практика, Vol 0, Iss 1, Pp 66-76 (2018)

Θεματικοί όροι: фармакоэкономика, анализ минимизации затрат, нестероидные противовоспалительные препараты, остеоартроз, ревматоидный артрит, мелоксикам, диклофенак, нимесулид, целекоксиб, эторикоксиб, pharmacoeconomics, cost minimization analysis, nonsteroidal anti-inflammatory drugs, osteoarthritis, rheumatoid arthritis, meloxicam, diclofenac, nimesulide, celecoxib, etoricoxib, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

Περιγραφή αρχείου: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/9; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

Σύνδεσμος πρόσβασης: https://doaj.org/article/1b43441bc83248f8a83a367850b260db

Etoricoxib can be used for chronic nonspecific back pain: a new indication of the well-known drug ; Эторикоксиб может использоваться при хронической неспецифической боли в спине: новое показание для хорошо известного препарата

Συγγραφείς: A. E. Karateev, А. Е. Каратеев

Συνεισφορές: This article has been supported by MSD., Статья спонсируется компанией «МСД Фармасьютикалс».

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 2 (2020); 125-130 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 2 (2020); 125-130 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-2

Θεματικοί όροι: безопасность, chronic nonspecific back pain, nonsteroidal anti-inflammatory drugs, etoricoxib, efficacy, safety, хроническая неспецифическая боль в спине, нестероидные противовоспалительные препараты, эторикоксиб, эффективность

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1317/1041; Парфенов ВА, Яхно НН, Кукушкин МЛ и др. Острая неспецифическая (скелетномышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2018;10(2):4–11. doi:10.14412/2074-2711-2018-2-4-11; Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Apr 4;166(7): 514-530. doi:10.7326/M16-2367. Epub 2017 Feb 14.; Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018 Nov; 27(11):2791-2803. doi:10.1007/s00586-018-5673-2. Epub 2018 Jul 3.; Bernstein IA, Malik Q, Carville S, Ward S. Low back pain and sciatica: summary of NICE guidance. BMJ. 2017 Jan 6;356:i6748. doi:10.1136/bmj.i6748.; Allegri M, Montella S, Salici F, et al. Mechanisms of low back pain: a guide for diagnosis and therapy. Version 2. F1000Res. 2016 Jun 28 [revised 2016 Oct 11];5. pii: F1000 Faculty Rev-1530. eCollection 2016.; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159): 1789-1858. doi:10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.; Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009-2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11): 1688-1694. doi:10.1002/acr.22890.; Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009 Jan-Feb;22(1): 62-8. doi:10.3122/jabfm.2009.01.080102.; Langenmaier AM, Amelung VE, Karst M, et al. Subgroups in chronic low back pain patients – a step toward cluster-based, tailored treatment in inpatient standard care: On the need for precise targeting of treatment for chronic low back pain. Ger Med Sci. 2019 Sep 11;17:Doc09. doi:10.3205/000275. eCollection 2019.; Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2):216-241.; Vardeh D, Mannion RJ, Woolf CJ. Toward a Mechanism-Based Approach to Pain Diagnosis. J Pain. 2016 Sep;17(9 Suppl):T50-69. doi:10.1016/j.jpain.2016.03.001.; Chou R, Deyo R, Friedly J, et al. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017 Apr 4;166(7):480-492. doi:10.7326/M16-2458. Epub 2017 Feb 14.; Ramos-Remus CR, Hunsche E, Mavros P, et al. Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico. Curr Med Res Opin. 2004 May;20(5):691-8.; Sheldon EA, Bird SR, Smugar SS, Tershakovec AM. Correlation of measures of pain, function, and overall response: results pooled from two identical studies of etoricoxib in chronic low back pain. Spine (Phila Pa 1976). 2008 Mar 1;33(5):533-8. doi:10.1097/BRS.0b013e3181657d24.; Peloso PM, Moore RA, Chen WJ, et al. Osteoarthritis patients with pain improvement are highly likely to also have improved quality of life and functioning. A post hoc analysis of a clinical trial. Scand J Pain. 2016 Oct;13: 175-181. doi:10.1016/j.sjpain.2016.07.002. Epub 2016 Aug 10.; Kuritzky L, Samraj GP. Nonsteroidal antiinflammatory drugs in the treatment of low back pain. J Pain Res. 2012;5:579-90. doi:10.2147/JPR.S6775. Epub 2012 Nov 28.; O'Donnell JB, Ekman EF, Spalding WM, et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009 Nov-Dec; 37(6):1789-802.; Krebs EE, Gravely A, Nugent S, et al. Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial. JAMA. 2018 Mar 6;319(9): 872-882. doi:10.1001/jama.2018.0899.; Ahmedani BK, Peterson EL, Wells KE, et al. Long-term Management of Low Back Pain with Opioids and Non-steroidal Anti-inflammatory Drugs in a Health System. Am J Prev Med. 2016 Jun;50(6):e191-e193. doi:10.1016/j.amepre.2016.02.001. Epub 2016 Mar 9.; Enthoven WT, Roelofs PD, Deyo RA, et al. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev. 2016 Feb 10;2:CD012087. doi:10.1002/14651858; Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ, и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018;56(1S):1-29. doi:10.14412/1995-4484-2018-1-29; Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005 May;39(5):854-62. Epub 2005 Apr 12.; Takemoto JK, Reynolds JK, Remsberg CM, et al. Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin Pharmacokinet. 2008;47(11):703-20.; Kwiatkowska B, Majdan M, MastalerzMigas A, et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55(6):290-297. doi:10.5114/reum.2017.72626. Epub 2017 Dec 30.; Давыдов ОС. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования ЦОГ 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):10–6. doi:10.14412/2074-2711-2016-2-10-16; Piirainen A, Kokki M, Hautajä rvi H, et al. The Cerebrospinal Fluid Distribution of Postoperatively Administred Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Markers in Patients Undergoing Hip Arthroplasty. Clin Drug Investig. 2016 Jul; 36(7):545-55. doi:10.1007/s40261-016-0400-4.; Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi:10.1186/s12891-016-1170-0.; Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal antiinflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6):1152-60. doi:10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.; Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov; 28(6):1021-1028. doi:10.1080/14397595.2018.1439694. Epub 2018 Mar 1.; Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.; Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi:10.1097/j.pain.0000000000000562.; Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Aug 2. pii: S1063-4584(17)31091-9.; Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain. 2003 Aug;4(6):307-15.; Pallay RM, Seger W, Adler JL, et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004;33(4):257-66.; Moore RA, Smugar SS, Wang H, et al. Numbers-needed-to-treat analyses – do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials. Pain. 2010 Dec;151(3): 592-7. doi:10.1016/j.pain.2010.07.013.; Zerbini C, Ozturk ZE, Grifka J, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, doubleblind study. Curr Med Res Opin. 2005 Dec; 21(12):2037-49.; Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005 May;21(5):715-22.; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A metaanalysis. PLoS One. 2018 Jan 10;13(1):e0190798. doi:10.1371/journal.pone.0190798. eCollection 2018.; Каратеев АЕ, Погожева ЕЮ, Филатова ЕС, Амирджанова ВН. Эндоскопическая картина верхних отделов желудочно-кишечного тракта на фоне приема различных нестероидных противовоспалительных препаратов. Клиническая фармакология и терапия. 2018;27(4):40-5.; Curtis S, Ko A, Bolognese J, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006 Dec;22(12): 2365-74.; Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006 Nov 18;368(9549):1771-81.; Каратеев АЕ. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018;12(2):64-72. doi:10.14412/1996-7012-2018-2-64-72; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79.; Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Expert Rev Clin Pharmacol. 2016 Sep 8:1-14.; Curtis SP, Ng J, Yu Q, et al. Renal effects of etoricoxib and comparator nonsteroidal antiinflammatory drugs in controlled clinical trials. Clin Ther. 2004 Jan;26(1):70-83.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1317
https://doi.org/10.14412/2074-2711-2020-2-125-130

Facet joint osteoarthritis as a cause of chronic low back pain ; Остеоартрит фасеточных суставов как причина хронической поясничной боли

Συγγραφείς: D. O. Rozhkov, O. E. Zinovyeva, A. N. Barinov, A. M. Nosovsky, Д. О. Рожков, О. Е. Зиновьева, А. Н. Баринов, А. М. Носовский

Συνεισφορές: Публикация статьи поддержана ООО «МСД Фармасьютикалс».

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 4 (2019); 176-181 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 4 (2019); 176-181 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-4

Θεματικοί όροι: Аркоксиа, backache, facet syndrome, nociplastic pain, musculoskeletal pain, myofascial pain syndrome, myoplasticity, pain catastrophizing, interventional therapy, cognitive behavioral therapy, rehabilitation, etoricoxib, Arcoxia, боль в спине, фасеточный синдром, ноципластическая боль, скелетно-мышечная боль, миофасциальный болевой синдром, миопластичность, катастрофизация, интервенционная терапия, когнитивно-поведенческая терапия, реабилитация, эторикоксиб

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1241/989; Global Burden of Disease Study 2013 Collaborators. Lancet. 2015 Aug 22; 386(9995):743-800.; Hoy D, Brooks P, Blyth F, Buchbinder R. The Epidemiology of low back pain. Best Pract Res Clin Rheumatol. 2010 Dec;24(6):769-81.; Balague F, Mannion AF, Pellise F, et al. Nonspecific low back pain. Lancet. 2012 Feb 4; 379(9814):482-91. doi:10.1016/S0140-6736 (11)60610-7. Epub 2011 Oct 6.; Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016; 54(3):247-65. doi:10.14412/1995-4484-2016-247-265; Алексеев ВВ, Баринов АН, Кукушкин МЛ и др. Боль: руководство для врачей и студентов. Москва: МЕДпресс-информ; 2009. 302 с.; Perolat R, Kastler A, Nicot B, et al. Facet joint syndrome: from diagnosis to interventional management. Insights Imaging. 2018 Oct;9(5): 773-789. doi:10.1007/s13244-018-0638-x; Баринов АН. Сегментарные механизмы формирования мышечного спазма, спастичности и хронизации боли. Врач. 2012;(5): 17–23.; Giesecke T, Gracely RH, Grant MA, et al. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum. 2004 Feb;50(2):613-23.; Kosek M, Cohen R, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016 Jul;157(7):1382-6. doi:10.1097/j.pain.0000000000000507.; Pergolizzi J, Ahlbeck K, Aldington D, et al . The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors? Curr Med Res Opin. 2012 Feb;28(2):249-56. doi:10.1185/03007995.2011.651525. Epub 2012 Jan 19.; Treede RD. The International Association for the Study of Pain definition of pain: as valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain Rep. 2018 Mar 5;3(2): e643. doi:10.1097/PR9.0000000000000643; Chou R, Deyo R, Friedly J, et al. Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):480-492.; Qaseem A, Wilt TJ, McLean RL, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017; 166(7):514-530.; Kalichman L, Kim DH, Li L, et al. Computed tomography-evaluated features of spinal degeneration: prevalence, intercorrelation, and association with self-reported low back pain. Spine J. 2010 Mar;10(3):200-8. doi:10.1016/j.spinee.2009.10.018; Goode AP, Marshall SW, Renner JB, et al. Lumbar spine radiographic features and demographic, clinical, and radiographic knee, hip, and hand osteoarthritis. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1536-44. doi:10.1002/acr.21720; Ko S, Vaccaro AR, Lee S, et al. The prevalence of lumbar spine facet joint osteoarthritis and its association with low back pain in selected Korean populations. Clin Orthop Surg. 2014 Dec;6(4):385-91. doi:10.4055/cios.2014.6.4.385.; Saravanakumar K, Harvey A. Lumbar zygapophyseal (facet) joint pain. Rev Pain. 2008 Sep;2(1):8-13. doi:10.1177/204946370800200103.; Datta S, Lee M, Falco FJ, et al. Systematic assessment of diagnostic accuracy and therapeutic utility of lumbar facet joint interventions. Pain Physician. 2009 Mar-Apr;12(2):437-60.; Gellhorn AC, Katz JN, Suri P. Osteoarthritis of the spine: the facet joints. Nat Rev Rheumatol. 2013 Apr;9(4):216-24. doi:10.1038/nrrheum.2012.199.; Sullivan MJ, D'Eon JL. Relation between catastrophizing and depression in chronic pain patients. J Abnorm Psychol. 1990 Aug; 99(3):260-3.; Парфенов ВА. Причины, диагностика и лечение боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2009;1(1):19-22. doi:10.14412/2074-2711-2009-17; Суслова ЕЮ, Парфенов ВА. Комплексный подход к лечению пациентов с хронической люмбалгией. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 115(10):16-21.; Arendt-Nielsen L. Evidence for a central mode of action for etoricoxib (COX-2 Inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi:10.1097/j.pain.0000000000000562.; Jung SY, Jang EJ, Nam SW, et al. Comparative Effectiveness of Oral Pharmacologic Interventions for Knee Osteoarthritis: A Network Meta-analysis. Mod Rheumatol. 2018 Nov;28(6):1021-1028. doi:10.1080/14397595.2018.1439694. Epub 2018 Mar 1.; Епифанов ВА, Епифанов АВ, Баринов АН. Боль в спине. Москва: МЕДпресс-информ; 2017. 130 с.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1241
https://doi.org/10.14412/2074-2711-2019-4-176-181

The therapeutic potential of etoricoxib in clinical practice ; Терапевтический потенциал эторикоксиба в клинической практике

Συγγραφείς: A. E. Karateev, А. Е. Каратеев

Πηγή: Modern Rheumatology Journal; Том 14, № 1 (2020); 108-117 ; Современная ревматология; Том 14, № 1 (2020); 108-117 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2020-1

Θεματικοί όροι: кардиоваскулярные осложнения, etoricoxib, efficacy, safety, gastrointestinal tract, cardiovascular complications, эторикоксиб, эффективность, безопасность, желудочно-кишечный тракт

Περιγραφή αρχείου: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1001/960; Van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth. 2013 Jul;111(1):13-8. doi:10.1093/bja/aet123; Lestoquoy AS, Laird LD, Mitchell S, et al. Living with chronic pain: Evaluating patient experiences with a medical group visit focused on mindfulness and non-pharmacological strategies. Complement Ther Med. 2017 Dec;35:33-8. doi:10.1016/j.ctim.2017.09.002. Epub 2017 Sep 12.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 446 с. ISBN 978-5-9704-4261-6; GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic anlysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi:10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.; Shmagel A, Foley R, Ibrahim H. Epidemiology of Chronic Low Back Pain in US Adults: Data From the 2009–2010 National Health and Nutrition Examination Survey. Arthritis Care Res (Hoboken). 2016 Nov;68(11):1688-94. doi:10.1002/acr.22890; Deyo R, Mirza S, Turner J, Martin B. Overtreating chronic back pain: time to back off? J Am Board Fam Med. 2009;22(1):62-8. doi:10.3122/jabfm.2009.01.080102; Nagakura Y. The need for fundamental reforms in the pain research field to develop innovative drugs. Expert Opin Drug Discov. 2017 Jan;12(1):39-46. doi:10.1080/17460441.2017.1261108. Epub 2016 Nov 22.; Peppin JF, Cheatle MD, Kirsh KL, McCarberg BH. The complexity model: a novel approach to improve chronic pain care. Pain Med. 2015 Apr;16(4):653-66. doi:10.1111/pme.12621. Epub 2015 Mar 6.; Conaghan PG, Peloso PM, Everett SV, et al. Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. Rheumatology (Oxford). 2015 Feb;54(2): 270-7. doi:10.1093/rheumatology/keu332. Epub 2014 Aug 23.; Picavet HSJ, Monique Verschuren WM, Groot L, et al. Pain over the adult life course: 15-year pain trajectories – The Doetinchem Cohort Study. Eur J Pain. 2019 Oct;23(9): 1723-32. doi:10.1002/ejp.1450. Epub 2019 Jul 25.; Bastick AN, Wesseling J, Damen J, et al. Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective cohort study (CHECK). Br J Gen Pract. 2016 Jan;66(642):e32-9. doi:10.3399/bjgp15X688129. Epub 2015 Dec 6.; Fornasari D. Pain mechanisms in patients with chronic pain. Clin Drug Investig. 2012 Feb;32 Suppl 1:45-52. doi:10.2165/11630070-000000000-00000; Arendt-Nielsen L, Morlion B, Perrot S, et al. Assessment and manifestation of central sensitisation across different chronic pain conditions. Eur J Pain. 2018 Feb;22(2): 216-41. doi:10.1002/ejp.1140; Vardeh D, Mannion RJ, Woolf CJ. Toward a mechanism-based approach to pain diagnosis. J Pain. 2016 Sep;17(9 Suppl): T50-69. doi:10.1016/j.jpain.2016.03.001; Salaffi F, Giacobazzi G, Di Carlo M. Chronic pain in inflammatory arthritis: mechanisms, metrology, and emerging targets – A focus on the JAK-STAT pathway. Pain Res Manag. 2018 Feb 7;2018:8564215. doi:10.1155/2018/8564215. eCollection 2018.; Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019 Jun;15(6):355-63. doi:10.1038/s41584-019-0221-y; Каратеев АЕ, Насонов ЕЛ, Ивашкин ВТ и др.; Ассоциация ревматологов России, Российское общество по изучению боли, Российская гастроэнтерологическая ассоциация, Российское научное медицинское общество терапевтов, Ассоциация травматологов-ортопедов России, Российская ассоциация паллиативной медицины. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56 Прил. 1:1-29. doi:10.14412/1995-4484-2018-1-29; Kawahara K, Hohjoh H, Inazumi T, et al. Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta. 2015 Apr;1851(4): 414-21. doi:10.1016/j.bbalip.2014.07.008. Epub 2014 Jul 17.; Grö sch S, Niederberger E, Geisslinger G. Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain. Expert Opin Investig Drugs. 2017 Jan;26(1):51-61. doi:10.1080/13543784.2017.1260544. Epub 2016 Nov 20.; Salvado MD, Alfranca A, Haeggström JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med. 2012 Apr;18(4):233-43. doi:10.1016/j.molmed.2012.02.002. Epub 2012 Mar 17.; Nadda N, Vaish V, Setia S, Sanyal SN. Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother. 2012 Sep;66(6):474-83. doi:10.1016/j.biopha.2012.04.002. Epub 2012 May 10.; Kim HS, Kim T, Kim MK, et al. Cyclooxygenase-1 and -2: molecular targets for cervical neoplasia. J Cancer Prev. 2013 Jun;18(2):123-34. doi:10.15430/JCP. 2013.18.2.123; Tanwar L, Piplani H, Sanyal S. Anti-proliferative and apoptotic effects of etoricoxib, a selective COX-2 inhibitor, on 1,2-dimethylhydrazine dihydrochlorideinduced colon carcinogenesis. Asian Pac J Cancer Prev. 2010;11(5):1329-33.; Dong X, Hu Y, Jing L, Chen J. Role of phosphorylated extracellular signal-regulated kinase, calcitonin gene-related peptide and cyclooxygenase-2 in experimental rat models of migraine. Mol Med Rep. 2015 Aug;12(2): 1803-9. doi:10.3892/mmr.2015.3616. Epub 2015 Apr 15.; Eisenach JC, Curry R, Tong C, et al. Effects of intrathecal ketorolac on human experimental pain. Anesthesiology. 2010 May; 112(5):1216-24. doi:10.1097/ALN. 0b013e3181d94d8b; Jakubowski M, Levy D, Kainz V, et al. Sensitization of central trigeminovascular neurons: blockade by intravenous naproxen infusion. Neuroscience. 2007 Aug 24;148(2): 573-83. doi:10.1016/j.neuroscience.2007.04.064. Epub 2007 Jul 25.; Martina S, Vesta K, Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother. 2005;39(5):854-62. doi:10.1345/aph.1E543; Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther. 2004 May; 26(5):667-79. doi:10.1016/S0149-2918(04) 90067-7; Kwiatkowska B, Majdan M, Mastalerz-Migas A, et al. Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion. Reumatologia. 2017;55(6): 290-7. doi:10.5114/reum.2017.72626. Epub 2017 Dec 30.; Moore RA, Derry S, Aldington D, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015 Sep 28;(9):CD008659. doi:10.1002/14651858.CD008659.pub3; Moore RA, Straube S, Paine J, et al. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain. 2011 May; 152(5):982-9. doi:10.1016/j.pain.2010.11.030; Isola G, Matarese G, Alibrandi A, et al. Comparison of effectiveness of etoricoxib and diclofenac on pain and perioperative sequelae after surgical avulsion of mandibular third molars: A randomized, controlled, clinical trial. Clin J Pain. 2019 Nov;35(11):908-15. doi:10.1097/AJP.0000000000000748; Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi:10.1007/s10067- 015-2991-1. Epub 2015 Jun 24.; Lin TM, Chi JE, Chang CC, Kang YN. Do etoricoxib and indometacin have similar effects and safety for gouty arthritis? A metaanalysis of randomized controlled trials. J Pain Res. 2018 Dec 19;12:83-91. doi:10.2147/JPR.S186004. eCollection 2019.; Bickham K, Kivitz AJ, Mehta A, et al. Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of rheumatoid arthritis in a double-blind, randomized controlled trial. BMC Musculoskelet Disord. 2016 Aug 8;17:331. doi:10.1186/s12891-016-1170-0; Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal antiinflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016 Jun;75(6): 1152-60. doi:10.1136/annrheumdis-2015-207677. Epub 2015 Aug 6.; Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal antiinflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016 May 21; 387(10033):2093-105. doi:10.1016/S0140-6736(16)30002-2; Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018 Nov;28(6):1021-8. doi:10.1080/14397595.2018.1439694. Epub 2018 Mar 1.; Zacher J, Feldman D, Gerli R, et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin. 2003;19(8):725-36. doi:10.1185/030079903125002469; Reginster J, Malmstrom K, Mehta A, et al. Evalution of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66(7): 945-51. doi:10.1136/ard.2006.059162; Давыдов ОС. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования ЦОГ 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика. 2016;8(2):10-6. doi:10.14412/2074-2711- 2016-2-10-16; Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017;25(11):1781-91. doi:10.1016/j.joca.2017.07.009; Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005; 21(5):715-22. doi:10.1185/030079905X43686; Hunt R, Harper S, Watson D, et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003;98(8): 1725-33. doi:10.1111/j.1572-0241.2003.07598.x; Watson D, Bolognese J, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. Curr Med Res Opin. 2004;20(12):1899-908. doi:10.1185/030079904X12681; Feng X, Tian M, Zhang W, Mei H. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One. 2018 Jan 10; 13(1):e0190798. doi:10.1371/journal.pone.0190798. eCollection 2018.; Каратеев АЕ, Погожева ЕЮ, Филатова ЕС, Амирджанова ВН. Эндоскопическая картина верхних отделов желудочнокишечного тракта на фоне приема различных нестероидных противовоспалительных препаратов. Клиническая фармакология и терапия. 2018;27(4):40-5.; Curtis S, Ko A, Bolognese J, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib. Curr Med Res Opin. 2006;22(12):2365-74. doi:10.1185/030079906X148238; Cannon C, Sean P Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368:1771-81. doi:10.1016/S0140-6736(06)69666-9; Lin H, Cheng T, Wang J, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010;13(2):144-50. doi:10.1111/j.1756-185X.2010.01468.x; Каратеев АЕ. Дестабилизация артериальной гипертензии как осложнение терапии нестероидными противовоспалительными препаратами: значение проблемы. Современная ревматология. 2018;12(2): 64-72. doi:10.14412/1996-7012-2018-2-64-72; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi:10.1016/S0140-6736(13)60900-9; Kristensen LE, Jakobsen AK, Askling J, et al. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study. Arthritis Care Res (Hoboken). 2015 Aug;67(8): 1137-49. doi:10.1002/acr.22555; Zingler G, Hermann B, Fischer T, Herdegen T. Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks. Exp Rev Clin Pharmacol. 2016 Sep 8:1-14.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/1001
https://doi.org/10.14412/1996-7012-2020-1-108-117

Management of patients with acute lumbodynia and lumbar ischialgia in outpatient settings

Συγγραφείς: V. A. Parfyonov, L. M. Antonenko, N. V. Lebedeva

Πηγή: Медицинский совет, Vol 0, Iss 8, Pp 38-43 (2016)

Θεματικοί όροι: острая люмбалгия, etoricoxib, аркоксиа, arcoxia, Medicine, эторикоксиб, острая люмбоишиалгия, acute lumbar ischialgia, 3. Good health

Σύνδεσμος πρόσβασης: https://www.med-sovet.pro/jour/article/download/1303/1263
https://doaj.org/article/8540f61e01694948a3a83d0b496ff3e9
https://cyberleninka.ru/article/n/vedenie-patsientov-s-ostroy-lyumbalgiey-i-lyumboishialgiey-v-ambulatornoy-praktike
https://www.med-sovet.pro/jour/article/view/1303

DEVELOPMENT AND VALIDATION THE METHOD OF QUANTITATIVE DETERMINATION OF ETORICOXIB IN SOLID PHARMACEUTICAL FORMS BY HPLC ; РАЗРАБОТКА И ВАЛИДАЦИЯ МЕТОДИКИ КОЛИЧЕСТВЕННОГО ОПРЕДЕЛЕНИЯ ЭТОРИКОКСИБА В ТВЕРДЫХ ЛЕКАРСТВЕННЫХ ФОРМАХ МЕТОДОМ ВЭЖХ

Συγγραφείς: T. L. Batalova, O. A. Ostapyuk, K. R. Saveleva, T. Y. Andreevicheva, L. V. Persanova, S. V. Polyakov, V. N. Shestakov, Т. Л. Баталова, О. А. Остапюк, К. Р. Савельева, Т. Ю. Андреевичева, Л. В. Персанова, С. В. Поляков, В. Н. Шестаков

Πηγή: Drug development & registration; № 1 (2018); 90-95 ; Разработка и регистрация лекарственных средств; № 1 (2018); 90-95 ; 2658-5049 ; 2305-2066

Θεματικοί όροι: высокоэффективная жидкостная хроматография, etoricoxib, HPLC, эторикоксиб

Περιγραφή αρχείου: application/pdf

Relation: https://www.pharmjournal.ru/jour/article/view/551/546; А.M. Kaushal, А.K. Chakraborti, A.K. Bansal. FTIR Studies on Differential Intermolecular Association in Crystalline and Amorphous States of Structurally Related Non-Steroidal Anti- Inflammatory Drugs. URL: https://www.ncbi.nlm.nih.gov/pubmed/19434918 (дата обращения 10.01.2018).; P.S. Gangane, S.M. Bagde, S.G. Mujbaile, K.D. Niranjane. Development and Validation of HPLC Assay Method for Etoricoxib in Bulk Drug and Tablet Formulation. URL: http://www.ijser.in/archives/v2i6/SjIwMTMzMDk=.pdf (дата обращения 10.01.2018).; B. Hinz, K. Brune. Cyclooxygenase-2 - 10 yearslater // J. Pharmacol. Exp. Ther. 2002. № 300(2). P. 367-375.; H. Vanegas, H. Schaible. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord // Prog. Neurobiol. 2001. № 64(4). P. 327-363.; ОФС.1.1.0012.15. Валидация аналитических методик / Государственная фармакопея Российской Федерации. XIII изд. Т. 1. С. 222.; https://www.pharmjournal.ru/jour/article/view/551

Διαθεσιμότητα: https://www.pharmjournal.ru/jour/article/view/551

Differential chemoreactome analysis of synergistic combinations of tolperisone and nonsteroidal anti-inflammatory drugs ; Дифференциальный хемореактомный анализ синергидных комбинаций толперизона и нестероидных противовоспалительных препаратов

Συγγραφείς: I. Yu. Torshin, O. A. Gromova, L. V. Stakhovskaya, V. A. Semenov, A. N. Gromov, И. Ю. Торшин, О. А. Громова, Л. В. Стаховская, В. А. Семёнов, А. Н. Громов

Συνεισφορές: Работа выполнена по гранту РФФИ № 18-07-00944 и № 17-07-01419

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 2 (2019); 78-85 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 2 (2019); 78-85 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-2

Θεματικοί όροι: большие данные, diclofenac, meloxicam, dexketoprofen, etoricoxib, naproxen, chemoreactome analysis of synergism, big data, диклофенак, мелоксикам, декскетопрофен, эторикоксиб, напроксен, хемореактомный анализ синергизма

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1104/882; Машковский МД. Лекарственные средства. 17-е изд. Москва: Новая Волна; 2014. С. 98—9.; Торшин ИЮ, Громова ОА, Стаховская ЛВ, Семёнов ВА. Хемореактомный анализ молекул толперизона, тизанидина и баклофена: холинолитические, спазмолитические и анальгетические механизмы действия. Неврология, нейропсихиатрия, психосоматика. 2018;10(4):72-80. doi:10.14412/2074-2711-2018-4-72-80; Torshin IYu. Bioinformatics in the postgenomic era: physiology and medicine. New York: NovaBiomedicalBooks; 2007.; Torshin IY, Rudakov KV. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 1: fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2014;24(1):11-23.; Torshin IY, Rudakov KV. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 2: local completeness of invariants of chemographs in view of the combinatorial theory of solvability. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2014;24(2):196-208.; Torshin IY, Rudakov KV. On the theoretical basis of the metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2015;25(4):577–87.; Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017;27(1):16-28.; Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2017;27(2):184-99.; Torshin IY. Optimal dictionaries of the final information on the basis of the solvability criterion and their applications in bioinformatics. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2013;23(2):319-27.; Torshin IY, Rudakov KV. On metric spaces arising during formalization of recognition and classification problems. Part 1: Properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016;26(2):274–284.; Torshin IY, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Part 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications). 2016;26(3):483-96.; Galluzzi L, Lopez-Soto A, Kumar S, Kroemer G. Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity. 2016 Feb 16;44(2):221-31. doi:10.1016/j.immuni.2016.01.020.; Sollberger G, Strittmatter GE, Garstkiewicz M, et al. Caspase-1: the inflammasome and beyond. Innate Immun. 2014 Feb;20(2):115-25. doi:10.1177/1753425913484374. Epub 2013 May 15.; Ladha S, Qiu X, Casal L, et al. Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli. Cell Death Discov. 2018 Mar 12;4:40. doi:10.1038/s41420018-0043-8. eCollection 2018.; Monie TP, Bryant CE. Caspase-8 functions as a key mediator of inflammation and pro-IL-1processing via both canonical and non-canonical pathways. Immunol Rev. 2015 May;265(1):181-93. doi:10.1111/imr.12284.; Парфенов ВА, Яхно НН, Кукушкин МЛ и др. Острая неспецифическая (скелетномышечная) поясничная боль. Рекомендации Российского общества по изучению боли (РОИБ). Неврология, нейропсихиатрия, психосоматика. 2018;10(2):4–11. doi:10.14412/2074-2711-2018-2-4-11; Pareek A, Chandurkar N, Chandanwale A, et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, doubledummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J. 2009;18(12):1836-42. doi:10.1007/s00586-0091019-4; Андреев АВ, Громова ОА, Скоромец АА. Применение мидокалмовых блокад в лечении спондилогенных поясничных болевых синдромов. Результаты двойного слепого исследования. Русский медицинский журнал. 2002;10(21):968-72.; Fischoff D, Spivakovsky S. Are pharmacological treatments for oro-facial pain effective? Evid Based Dent. 2018 Mar 23;19(1):28-29. doi:10.1038/sj.ebd.6401294.; Герасимова ОН, Парфенов ВА, Калимеева ЕЮ. Лечение пациентов с острой и подострой дорсалгией. Неврология, нейропсихиатрия, психосоматика. 2018;10(3):36–41. doi:10.14412/2074-2711-2018-3-36-41

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1104
https://doi.org/10.14412/2074-2711-2019-2-78-85

Facet joint osteoarthritis as a component of non-specific low back pain ; Остеоартрит фасеточных суставов как одна из составляющих неспецифической боли в спине

Συγγραφείς: O. S. Davydov, О. С. Давыдов

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 2S (2019): Спецвыпуск: боль в спине и конечностях; 76-82 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 2S (2019): Спецвыпуск: боль в спине и конечностях; 76-82 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-2S

Θεματικοί όροι: эторикоксиб, facet syndrome, facet joints osteoarthritis, nonsteroidal anti-inflammatory drugs, etoricoxib, фасеточный синдром, остеоартрит (остеоартроз) фасеточных суставов, нестероидные противовоспалительные препараты

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1124/905; Hoy D, Bain C, Williams G, et al. A systematic review of the global prevalence of low back pain. Arthritis Rheum. 2012;64(6):2028-37. doi:10.1002/art.34347; Balague F, Mannion AF, Pellise F, Cedraschi C. Non-specific low back pain. Lancet. 2012; 379:482-91. doi:10.1016/S0140-6736(11)60610-7; Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jun 7. pii: S0140-6736(15)60692-4; Матросов ДН, Галушко ЕА, Эрдес ШФ. Эпидемиология болей в нижней части спины в амбулаторной практике. Боль. 2009;4(25):23-8.; Яхно НН, Кукушкин МЛ, Чурюканов МВ, Сыровегин АВ. Результаты открытого мультицентрового исследования «МЕРИДИАН» по оценке распространенности болевых синдромов в амбулаторной практике и терапевтических предпочтений врачей. Российский журнал боли. 2012;3(36-37):10-4.; Knaggs R. Low back pain clinical guidelines: similarities and divergent views across the pond. Br J Pain. 2017 May;11(2):70. doi:10.1177/2049463717701809; Mehling WE, Gopisetty V, Bartmess E, et al. The prognosis of acute low back pain in primary care in the United States: a 2-year prospective cohort study. Spine (Phila Pa 1976). 2012 Apr 15;37(8):678-84. doi:10.1097/BRS.0b013e318230ab20; Itz CJ, Geurts JW, van Kleef M, Nelemans P. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013 Jan;17(1): 5-15. doi:10.1002/j.1532-2149.2012.00170.x; Freburger JK, Holmes GM, Agans RP, et al. The rising prevalence of chronic low back pain. Arch Intern Med. 2009 Feb 9;169(3):251-8. doi:10.1001/archinternmed.2008.543; Manchikanti L, Pampati VS, Fellows B, et al. Prevalence of lumbar facet joint pain in chronic low back pain. Pain Physician. 1999;2:59-64.; Schwarzer AC, Wang S, Bogduk N, et al. Prevalence and clinical features of lumbar zygapophysial joint pain: A study in an Australian population with chronic low back pain. Am Rheum Dis. 1995;54:100-6. doi:10.1136/ard.54.2.100; Bogduk N. Lumbar Facet Syndrome. In: Steven D. Waldman SD, ed. Pain Management. Philadelphia: W.B. Saunders; 2007. P. 769-76.; Varlotta GP, Lefkowitz TR, Schweitzer M, et al. The lumbar facet joint: a review of current knowledge: part 1: anatomy, biomechanics, and grading. Skeletal Radiol. 2011;40(1):13-23. doi:10.1007/s00256-010-0983-4; Igarashi A, Kikuchi S, Konno S, Olmarker K. Inflammatory cytokines released from the facet joint tissue in degenerative lumbar spinal disorders. Spine (Phila Pa 1976). 2004 Oct 1;29(19):2091-5. doi:10.1097/01.brs.0000141265.55411.30; Genevay S, Finckh A, Payer M, et al. Elevated levels of tumor necrosis factor-alpha in periradicular fat tissue in patients with radiculopathy from herniated disc. Spine (Phila Pa 1976). 2008 Sep 1;33(19):2041-6. doi:10.1097/BRS.0b013e318183bb86; Gellhorn AC, Katz JN, Suri P. Osteoarthritis of the spine: the facet joints. Nat Rev Rheumatol. 2013 Apr;9(4):216-24. doi:10.1038/nrrheum.2012.199; Воробьева ОВ. Фасеточный синдром как причина боли в спине. Эффективная фармакотерапия. 2012;(1):4-9.; Давыдов ОС, Павлова ЛВ, Жуков ЕВ. Фасеточный синдром. Врач. 2015;(10):8-14.; Van Kleef M, Vanelderen P, Cohen SP, et al. Pain originating from the lumbar facet joints. Pain Pract. 2010;10:459-69. doi:10.1111/j.1533-2500.2010.00393.x; Dwyer A, Aprill C, Bogduk N. Cervical zygapophyseal joint pain patterns. I: A study in normal volunteers. Spine (Phila Pa 1976). 1990 Jun;15(6):453-7. doi:10.1097/00007632-199006000-00004; Парфенов ВА, Исайкин АИ. Боли в поясничной области. Москва; 2018. 200 с.; Diez-Ulloa MA, Almira Suarez EL, Otero Fernandez M, et al. Lordosis manoeuvre in the diagnosis of lumbar facet syndrome. Rev Esp Cir Ortop Traumatol. 2016 Jul-Aug;60(4):221-6.; Gomez Vega JC, Acevedo-Gonzalez JC. Clinical diagnosis scale for pain lumbar of facet origin: systematic review of literature and pilot study. Neurocirugia (Astur). 2018 Jun 14. pii: S1130-1473(18)30051-4; Kalichman L, Li L, Kim D, et al. Facet joint osteoarthritis and low back pain in the community-based population. Spine (Phila Pa 1976). 2008;33:2560-5. doi:10.1097/BRS.0b013e318184ef95; Saal JS. General principles of diagnostic testing as related to painful lumbar spine disorders: a critical appraisal of current diagnostic techniques. Spine (Phila. Pa. 1976). 2002;27(22):2538-45. doi:10.1097/00007632-200211150-00027; Chou R, Hashimoto R, Friedly J, et al. Pain Management Injection Therapies for Low Back Pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar. AHRQ Technology Assessments.; Qaseem А, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514-30. doi:10.7326/M16-2367; Парфенов ВА, Яхно НН, Кукушкин МЛ и др. Острая неспецифическая (скелетномышечная) поясничная боль. Рекомендации Российского общества по изучению боли. Неврология, нейропсихиатрия, психосоматика. 2018;10(2):4-11. doi:10.14412/2074-2711-2018-2-4-11; Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016; 54(3):247-65. doi:10.14412/1995-4484-2016-247-265; Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2008;33:1766-74. doi:10.1097/BRS.0b013e31817e69d3; De Vecchis R, Baldi C, Di Biase G, et al. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen. Minerva Cardioangiol. 2014 Dec;62(6):437-48.; Ramey D, Watson D, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005;21(5):715-22. doi:10.1185/030079905X43686; Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placeboand active comparator-controlled dose-ranging study. Clin Ther. 2004 May;26(5):667-79. doi:10.1016/S0149-2918(04)90067-7; Moore R, Moore O, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-9. doi:10.1136/ard.2009.107805; Jung SY, Jang EJ, Nam SW, et al. Comparative Effectiveness of Oral Pharmacologic Interventions for Knee Osteoarthritis: A Network Meta-analysis, 2018. Modern Rheumatol. 2018;28(6). doi:10.1080/14397595.2018.1439694; Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Aug;157(8):1634-44. doi:10.1097/j.pain.0000000000000562; Moss P, Benson HAE, Will R, Wright A. Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2017 Nov;25(11):1781-91. doi:10.1016/j.joca.2017.07.009; Sharma L. Osteoarthritis year in review 2015: clinical. Osteoarthritis Cartilage. 2016 Jan;24(1):36-48. doi:10.1016/j.joca.2015.07.026; Cohen SP, Huang JH, Brummett C. Facet joint pain – advances in patient selection and treatment. Nat Rev Rheumatol. 2013;9(2):101- 16. doi:10.1038/nrrheum.2012.198; Manchikanti L, Helm S, Singh V. An algorithmic approach for clinical management of chronic spinal pain. Pain Physician. 2009;12(4): 225-64.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/1124
https://doi.org/10.14412/2074-2711-2019-2S-76-82

Pharmacoeconomic analysis of Movalis in patients with osteoarthritis and rheumatoid arthritis ; Фармакоэкономический анализ применения препарата Мовалис у больных с остеоартрозом и ревматоидным артритом

Συγγραφείς: E. S. Tsvetkova, D. Yu. Belousov, E. V. Afanasyeva, Е. С. Цветкова, Д. Ю. Белоусов, Е. В. Афанасьева

Συνεισφορές: Настоящий экономический анализ был профинансирован фармацевтической компанией «Берингер Ингельхайм», однако это не оказало влияние на результаты данного исследования.

Πηγή: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 1 (2015); 66-76 ; Качественная клиническая практика; № 1 (2015); 66-76 ; 2618-8473 ; 2588-0519

Θεματικοί όροι: etoricoxib, анализ минимизации затрат, нестероидные противовоспалительные препараты, остеоартроз, ревматоидный артрит, мелоксикам, диклофенак, нимесулид, целекоксиб, эторикоксиб, pharmacoeconomics, cost minimization analysis, nonsteroidal anti-inflammatory drugs, osteoarthritis, rheumatoid arthritis, meloxicam, diclofenac, nimesulide, celecoxib

Περιγραφή αρχείου: application/pdf

Relation: https://www.clinvest.ru/jour/article/view/9/9; Andersohn F., Schade R., Suissa S., Garbe E. Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke. // Stroke. 2006;37:1725-1730.; Antonov K.I.M., Isacson D.G.L. Prescription and non-prescription analgesic use in Sweden. Ann Pharmacoter 1998;32:485-94.; Arja Helin-Salmivaara, Arja Virtanen, Risto Vesalainen, Juha M. Gro?nroos, Timo Klaukka, Juhana E. Ida?npa?a?n-Heikkila?, and Risto Huupponen. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. // European Heart Journal (2006) 27, 1657-1663.; Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. // Gut 1987;28:527-32.; Blower A.L., Brooks A., Fenn G.C. et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. // Aliment Pharmacol Ther 1997;11:283-91.; Caputi A.P., Kong S.X. Concomitant use of gastroprotective agents among users of nonsteroidal anti-inflammatory drugs in Italy. The 14th EULAR Congress. Prague, 13-16 June, 2001.; Chang C., Shau W., Kuo C., Chen S., Lai M. Increased Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Case-Crossover Study. // Stroke. 2010;41:1884-1890.; Chen Y.F., Jobanputra P., Barton P. et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteorthritis and rheumatoid arthritis: a systematic review and economic evaluation. // Health Technology Assessment 2008;12:11.; Cockel R. NSAIDs - should every prescription carry a government health warning? // Gut 1987;28:515-8.; Cohen Y., Freeman N.L., Kong S.X. et al. Gastrointestinal health care resource use and costs associated with nonsteroidal anti-inflammatory drugs: analysis of a population cohort in Israel. The 14th EULAR Congress. Prague, 13-16 June, 2001.; Colberg K., Hettich M., Sigmund R. et al. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. German Meloxicam Ampoule Study Group. // Curr Med Res Opin 1996;13:363-77.; de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. // Scand J Rheumatol 1992;96(Suppl.):49-53.; Degner F., Lanes S., van Ryn J. et al. Pharmacological and clinical profile meloacam. Therapeutic roles of selective COX-2 inhibitors. Vane J.R., Botting RM. (Eds). London: William Harvey Press, 2001.; Del Tacca M., Colucci R., Fornai M. et al. Efficacy and tolerability of meloxicam, COX-2 preferential nonsteroidal anti-inflammatory drug. // Clin Drug Ivest 2002;22(12):799-818.; Dequeker J., Hawkey C., Kahan A. et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. // Brit J Rheumatol 1998;37(9):946-51.; Elliott A.M., Smith B.H., Penny K.L. et al. The epidemiology of chronic pain in the community. // Lancet 1999;354:1248-52.; Fries J.F. NSAID gastropathy: the second most deadly theumatic disease? Epidemiology and risk appraisal. // J Rheumatol 1991;28(Suppl.):6-10.; Hawkey C. et al. Gastrointestinal tolerability of meloxicam compared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. // Rheumatol (Oxford) 1999;38:793-8.; Hogan D.B., Campbell N.R. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. // Can Med Assoc J 1994;151:315-22.; Hurley J., Mucha L., Straus W. et al. NSAID and concomitant gastrointestinal drug use among cases and controls in a managed care population. // Gastroenterology 2000;118(Suppl.):A3914.; Jansen R.B., Capri S., Nuijten M.J.C. Economic evaluation of meloxicam (7,5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. // Brit J Med Econom 1997;11:9-22.; Hawkey C., Kahan A., Steinbruck K. et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. // Brit J Rheumatol 1998;37(9):937-45.; Kephart G., Sketris I., Smith M. et al. Coprescribing of nonsteroidal anti-inflammatory drugs and cytoprotective and antiulcer drugs in Nova Scotia’s senior population. // Clin Ther 1995;17:1159-73.; Knill-Jones R.P. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary of article by G. de Pouvourville. // Scand J Rheumatol 1992;96(Suppl.):59-62.; Laine L., Goldkind L., Curtis S.P., Connors L.G., et al. How Common Is Diclofenac-Associated Liver Injury? Analysis of17,289 Arthritis Patients in a Long-Term Prospective Clinical Trial. // The American Journal of gastroenterology. 2009, VOLUME 104, pp. 356-362.; Langman M.J., Kahler K.H., Kong S.X. et al. Use of gastroprotective agents and other healthcare resources among patients on nonsteroidal anti-inflammatory drugs in the United Kingdom. The 12th EULAR Congress. Glasgow, 6-11 June, 1999.; Laporte J., Ibanez L., Vadal X., Vendrell L., Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs. // Drug safety, 2004; 27 (6): 411-420.; Mangoni A.A., Woodman R.J., Ganis P., Gilbert A.L., Knights K.M. Use of non-steroidal anti-inflammatory drugs and risk of incident miocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. // British Journal of Clinical Pharmacology, 2010, 69:6, pp. 689-700.; Moore N., Montout C. Use of gastrointestinal protective agents among patients on nonsteroidal anti-inflammatory drugs in France and prevention of treatment of adverse GI effects. 12th EULAR Congress. Glasgow, 6-11 June, 1999.; Moore N., Verschuren X., Montout C. et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice. // Therapie 2000;55:133-6.; Moore R.A. The hidden costs of arthritis treatment and the cost of new therapy - the burden of non-steroidal anti-inflammatory drug gastropathy. // Rheumatology (Oxford) 2002;41(Suppl.1):7-15.; Moore R.A., Phillips C.J. Cost of NSAID adverse effects to the UK National Health Service. // J Med Econ 1999;156:2321-32.; Pfizer. Celecoxib Study 096 (SUCCESS-1). 2004 submission (commercial-in-confidence). 2004.; Rahme E., Joseph L., Kong S.X. et al. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. // Br J Clin Pharmacol 2001;52:185-92.; Rostom A., Goldkind L., Lain L. Nonsteroidal anti-inflammatory drugs and hepatic toxity: a systematic review of randomized controlled trials in arthritis patients. // Clin Gastroenterol Hepatol. 2005, 3:5, pp. 489-498.; Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. // JAMA 2000;284:1247-55.; Singh G. Recent considerations in nonsteroidal anti-inflammatory gastropathy. // Am J Med 1998;105:31S-38S.; Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. // American journal of medicine, 2004, Volume 117, pp.100-106.; Singh G., Ramey D.R. Gastrointestinal tract complications on nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. // Arch Inern Med 1996;156:1530-6.; Tavakoli M. Modelling Therapeutic Strategies in the Treatment of Osteoarthritis: An Economic Evaluation of Meloxicam Versus Diclofenac and Piroxicam. // Pharmacoeconomics 2003;21(6):443-54.; Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villinger P. V., Egger M., Juni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. // British Medical Journal, 2011, 342, pp.7086.; Аналитическая информация, IMS Россия, январь 2013 г. - сентябрь 2014 г. [Электронный ресурс]. URL:http://www.ims.ru/.; Насонова В.А., Воробьёв П.А., Цветкова ЕС. и др. Фармакоэкономический анализ применения двух нестероидных противовоспалительных препаратов в ревматологии. // Науч-практич ревматол 2002;1:63-8.; Отраслевой стандарт «Клинико-экономические исследования. Общие положения» Приказ Минздрава РФ от 27.05.2002 №163 вместе с ост 91500.14.0001-2002 [Электронный ресурс]. http://www.healtheconomics.ru/index.php?option=com_content&view=artide&id=300:-q-q&catid=55:2009-05-29-19-56-44&Itemid=104.; Ревматология: клинические рекомендации. // Под ред. акад. РАМН Е.Л. Насонова. - 2-е изд., испр. и доп. - М.: ГЭТОТАР-медиа, 2010 - 752 с.; Стандарт специализированной медицинской помощи при других заболеваниях печени, №772н.; Стандарт специализированной медицинской помощи при инфаркте мозга, №1740н.; Стандарт специализированной медицинской помощи при остром инфаркте миокарда с подьёмом сегмента ST электрокардиограммы, №907н.; Стандарт специализированной медицинской помощи при субарахноидальных, внутримозговых и неуточнённых кровоизлияниях, №1791н.; Стандарт специализированной медицинской помощи при язвенной болезни желудка, двенадцатиперстной кишки, №773н.; Тарифы на медицинские услуги Московского городского фонда ОМС, введённые в действие с 01.04.2014 г. [Электронный ресурс]. http://www.mgfoms.ru.; Шостак Н.А., Правдюк Н.Г., Клименко А.А., Кондрашов А.А. Болевой синдром в ревматологии. // Медицинский совет, №1, 2013 г., стр. 82-88.; Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Дисконтирование при проведении фармакоэкономических исследований. // Фармакоэкономика. 2009; №4: c.10-13.; Tramer M.R., Moore R.A., Reynolds D.J.M., et al. Qualitative estimation of rare adverse events which follow a biological pregression: a new model applied to chronic NSAID use. // Pain 2000;85:169-82.; https://www.clinvest.ru/jour/article/view/9

Διαθεσιμότητα: https://www.clinvest.ru/jour/article/view/9

Clinico-pharmacological aspects of choice and safety of NSAIDs in patients with cerebrovascular disease against a background of rheumatoid arthritis

Συγγραφείς: I. A. Zolotovskaya, I. E. Poverennova

Πηγή: Медицинский совет, Vol 0, Iss 5, Pp 108-111 (2014)

Θεματικοί όροι: нестероидные противовоспалительные препараты, цереброваскулярная патология, эторикоксиб, nonsteroidal anti-inflammatory drugs, cerebrovascular pathology, etoricoxib, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/576; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Σύνδεσμος πρόσβασης: https://doaj.org/article/69bf19f7f02c48ecabb6e8bab7c1b589

CHRONIC BACK PAIN: FROM PATHOGENETIC CONCEPTS TO THERAPEUTIC STRATEGIES ; ХРОНИЧЕСКАЯ БОЛЬ В СПИНЕ: ОТ ПАТОГЕНЕТИЧЕСКИХ КОНЦЕПЦИЙ К ТЕРАПЕВТИЧЕСКИМ СТРАТЕГИЯМ

Συγγραφείς: O. V. Vorobieva, О. В. Воробьева

Πηγή: Meditsinskiy sovet = Medical Council; № 17 (2017); 36-42 ; Медицинский Совет; № 17 (2017); 36-42 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-17

Θεματικοί όροι: эторикоксиб, peripheral and central sensitization, chronic neuroinflammation, etoricoxib, периферическая и центральная сенситизация, хроническое нейровоспаление

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2146/2128; Bakker EW, Verhagen AP, van Trijffel E, Lucas C, Koes BW. Spinal mechanical load as a risk factor for low back pain: a systematic review of prospective cohort studies. Spine, 2009, 34: E281–293.; Modic MT, Ross JS. Lumbar degenerative disk disease. Radiology, 2007 Oct, 245(1): 43-61.; Pearce RH, Grimmer BJ, Adams ME. Degeneration and the chemical composition of the human lumbar intervertebral disc. J Orthop Res, 1987, 5(2): 198-205.; Samartzis D, Karppinen J, Mok F, Fong DY, Luk KD, Cheung KM. A population-based study of juvenile disc degeneration and its association with overweight and obesity, low back pain, and diminished functional status. J Bone Joint Surg Am, 2011, 93(7): 662-670.; Gandhi R, Woo KM, Zywiel MG, Rampersaud YR. Metabolic syndrome increases the prevalence of spine osteoarthritis. Orthop Surg, 2014, 6(1): 23-27.; Siemionow K, An H, Masuda K, Andersson G, Cs-Szabo G. The effects of age, sex, ethnicity, and spinal level on the rate of intervertebral disc degeneration: a review of 1712 intervertebral discs. Spine (Phila Pa 1976), 2011 Aug 1, 36(17): 1333-1339.; Chou D, Samartzis D, Bellabarba C, Patel A, Luk KD, Kisser JM, Skelly AC. Degenerative magnetic resonance imaging changes in patients with chronic low back pain: a systematic review. Spine, 2011, 36(21 Suppl): S43–S53.; Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and Molecular Mechanisms of Pain. Cell, 2009, 139: 267-284.; Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci, 2009, 32: 611-618.; Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science, 2000, 288: 1765-1769.; Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev, 2014, 66(1): 80-101.; Ji RR, Berta T, Nedergaard M. Glia and pain: is chronic pain a gliopathy? Pain, 2013, 154(suppl 1): s10-s28.; Loggia ML et al. Evidence for brain glial activation in chronic pain patients. BRAIN. doi:10.1093/brain/awu377 First published online: 12 January 2015.; Давыдов О.С. Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования циклооксигеназы 2 в предотвращении хронизации болевого синдрома. Неврология, нейропсихиатрия, психосоматика, 2016, 8(2): 10-16.; Li Y, Liu J, Liu ZZ, Duan DP. Inflammation in low back pain may be detected from the peripheral blood: suggestions for biomarker. Biosci Rep, 2016 Aug 5, 36(4).; Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev, 2008, 1: CD000396.; Kuritzky L., Samraj GP. Nonsteroidal antiinflammatory drugs in the treatment of low back pain. Journal of Pain Research, 2012, 5: 579-590.; Renner B, Zacher J, Buvanendran A, et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Naunyn Schmiedebergs Arch Pharmacol, 2010 Feb, 381(2): 127-136.; Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 Inhibitor) in patients with painful knee osteoarthritis. Pain, 2016, 157: 1634-1644.; Данилов А.Б. ЦОГ-зависимые механизмы, участвующие в антиноцицептивном действии НПВП на центральном уровне. Manage Pain, 2014, 3.; Kew Y et al. Prevalence and associations of neuropathic pain in a cohort of multi-ethnic Asian low back pain patients. Rheumatol Int, 2017, 37: 633–639.; Давыдов О.С. и соавт. Фасеточный синдром. Врач, 2015, 10: 8-14.; Manchikanti L. et al. Prevalence of lumbar facet joint pain in chronic low back pain. Pain Physician, 1999, 2(3): 59-64.; Schwarzer AC et al. Prevalence and clinical features of lumbar zygapophysial joint pain: a study in an Australian population with chronic low back pain. Annals of the Rheumatic Diseases, 1995, 54: 100-106.; Lin HY et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. International Journal of Rheumatic Diseases, 2010, 13: 144–150.; Malmstrom K et al. Etoricoxib in acute pain associated with dental surgery: a randomized, double-blind, placeboand active comparatorcontrolled dose-ranging study. Clin Ther, 2004, 26(5): 667-679.; The 2007 Oxford league table of analgesic efficacy http: //www.bandolier.org.uk/booth/painpag/Acutrev/Analgesics/lftab.html.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/2146
https://doi.org/10.21518/2079-701X-2017-17-36-42

The peripheral and central mechanisms of transition of acute to chronic pain and the possible role of cyclooxygenase-2 inhibition in the prevention of pain syndrome chronization ; Периферические и центральные механизмы перехода острой боли в хроническую и возможная роль ингибирования циклооксигеназы 2 в предотвращении хронизации болевого синдрома

Συγγραφείς: O. S. Davydov, О. С. Давыдов

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 8, No 2 (2016); 10-16 ; Неврология, нейропсихиатрия, психосоматика; Vol 8, No 2 (2016); 10-16 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2016-2

Θεματικοί όροι: эторикоксиб, central and peripheral sensitization, disinhibition, nonsteroidal anti-inflammatory drugs, coxibs, etoricoxib, центральная и периферическая сенситизация: дизингибиция, нестероидные противовоспалительные препараты, коксибы

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/602/552; Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi:10.1016/S0140- 6736(15)60692-4. Epub 2015 Jun 7.; Яхно НН, Кукушкин МЛ, Чурюканов МВ, Сыровегин АВ. Результаты открытого мультицентрового исследования «МЕРИДИАН» по оценке распространенности болевых синдромов в амбулаторной практике и терапевтических предпочтений врачей. Российский журнал боли. 2012;(3):10-4. [Yakhno NN, Kukushkin ML, Churyukanov MV, Syrovegin AV. The results of an open multicenter study «MERIDIAN» on the assessment of the prevalence of pain syndromes in the outpatient clinic and therapeutic preferences of doctors. Rossiiskii zhurnal boli. 2012;(3):10-4. (In Russ.)].; Jackson T, Thomas S, Stabile V, et al. Prevalence of chronic pain in low-income and middleincome countries: a systematic review and meta-analysis. Lancet. 2015 Apr 27;385 Suppl 2:S10. doi:10.1016/S0140- 6736(15)60805-4. Epub 2015 Apr 26.; Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary Chronic Pain Management: Past, Present, and Future. Am Psychol. 2014 Feb-Mar;69(2):119-30. doi:10.1037/a0035514.; Gatchel RJ, Peng YB, Peters ML, et al. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007 Jul;133(4):581-624.; Данилов АБ. Управление болью. Биопси- хосоциальный подход. Москва: АММ ПРЕСС; 2012. 292 с. [Danilov AB. Upravlenie bol'yu. Biopsikhosotsial'nyi podkhod [The management of pain. Biopsychosocial approach]. Moscow: AMM PRESS; 2012. 292 p.]; Toth C. Peripheral and Central sensitization. In: Toth C, Moulin DE, editors. Neuropathic Pain: Causes, Management, and Understanding. Cambridge University Press; 2013. P. 51-64.; Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009 Sep;10(9):895-926. doi:10.1016/j.jpain.2009.06.012.; Кукушкин МЛ, Подчуфарова ЕВ, Яхно НН. Физиология и патофизиология боли. В кн.: Яхно НН, Кукушкин МЛ, редакторы. Боль (практическое руководство для врачей). Москва: Издательство РАМН; 2011. С.12-30. [Kukushkin ML, Podchufarova EV, Yakhno NN. Physiology and pathophysiology of pain. In: Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for physicians)]. Moscow: Izdatel'stvo RAMN; 2011. P.12-30.]; Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011 Mar;152(3 Suppl):S2-15. doi:10.1016/j.pain.2010.09.030. Epub 2010 Oct 18.; Handwerker H. Peripheral and central sensitization as risk factors of low back pain. In: Hasenbring MI, Rusu AC, Turk DC, editors. From Acute to Chronic Back Pain: Risk Factors, Mechanisms and Clinical Implications. Oxford: Oxford University Press; 2012. P. 287-310.; Arendt-Nielsen L. Central sensitization in humans: assessment and pharmacology. Handb Exp Pharmacol. 2015;227:79-102. doi:10.1007/978-3-662-46450-2_5.; Данилов АБ, Давыдов ОС. Биологические и патологические аспекты боли. В кн: Нейропатическая боль. Москва: Боргес; 2007. С. 56-69. [Danilov AB, Davydov OS Biological and pathological aspects of pain. In: Neiropaticheskaya bol' [Neuropathic pain]. Moscow: Borges; 2007. P. 56-69.]; Каратеев АЕ, Яхно НН, Лазебник ЛБ и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва: ИМА-ПРЕСС; 2009. 168 c. [Karateev AE, Yakhno NN, Lazebnik LB, et al. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii [The use of nonsteroidal antiinflammatory drugs. Clinical guidelines]. Moscow: IMA-PRESS; 2009. 168 p.]; Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001 Mar 22; 410(6827):471-5.; Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog Neurobiol. 2001 Jul;64(4):327-63.; Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992 Aug 28;257(5074):1276-9.; Yamamoto T, Sakashita Y. COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA. Neuroreport. 1998 Dec1;9(17):3869-73.; Euchenhofer C, Maihоfner C, Brune K, et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett. 1998 May 22;248(1):25-8.; Telleria-Diaz A, Schmidt M, Kreusch S, et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain. 2010 Jan;148(1):26-35.; Burns D, Hill L, Essandoh M, et al. Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers. BMC Anesthesiol. 2006 Mar 10;6:3.; Willert RP, Delaney C, Hobson AR, et al. Constitutive cyclooxygenase-2 does not contribute to the development of human visceral pain hypersensitivity. Eur J Pain. 2006 Aug;10(6):487-94. Epub 2005 Aug 24.; Martin F, Fletcher D, Chauvin M, Bouhassira D. Constitutive cyclooxygenase-2 is involved in central nociceptive processes in humans. Anesthesiology. 2007 May;106(5):1013-8.; Sycha T, Anzenhofer S, Lehr S, et al. Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. Pain. 2005 Feb;113(3):316-22.; Renner B, Zacher J, Buvanendran A, et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Naunyn Schmiedebergs Arch Pharmacol. 2010 Feb;381(2):127-36.; Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology. 2005 Feb;102(2):409-15.; Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 Inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Mar 22. [Epub ahead of print].; Croom KF, Siddiqui MA. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs. 2009 Jul 30;69(11):1513-32.; Lin HY, Cheng TT, Wang JH, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010 May;13(2):144-50.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/602
https://doi.org/10.14412/2074-2711-2016-2-10-16

Фармакоэкономический анализ применения препарата Мовалис у больных с остеоартрозом и ревматоидным артритом

Συγγραφείς: ЦВЕТКОВА Е.С., БЕЛОУСОВ ДМИТРИЙ ЮРЬЕВИЧ, АФАНАСЬЕВА Е.В.

Θεματικοί όροι: ФАРМАКОЭКОНОМИКА, АНАЛИЗ МИНИМИЗАЦИИ ЗАТРАТ, НЕСТЕРОИДНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ, ОСТЕОАРТРОЗ, РЕВМАТОИДНЫЙ АРТРИТ, МЕЛОКСИКАМ, ДИКЛОФЕНАК, НИМЕСУЛИД, ЦЕЛЕКОКСИБ, ЭТОРИКОКСИБ

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/farmakoekonomicheskiy-analiz-primeneniya-preparata-movalis-u-bolnyh-s-osteoartrozom-i-revmatoidnym-artritom
http://cyberleninka.ru/article_covers/15914780.png

Current principles in the management of patients with chronic nonspecific lumbago ; Современные принципы ведения пациентов с хронической неспецифической люмбалгией

Συγγραφείς: E.Yu. Suslova, O.A. Chernenko, Е.Ю. Суслова, О.А. Черненко

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 6, No 2 (2014); 81-85 ; Неврология, нейропсихиатрия, психосоматика; Vol 6, No 2 (2014); 81-85 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2014-2

Θεματικοί όροι: мультидисциплинарный подход, chronic lumbago, treatment, nonsteroidal anti-inflammatory drugs, etoricoxib, cognitive-behavioral therapy, multidisciplinary approach, хроническая люмбалгия, лечение, нестероидные противовоспали- тельные препараты, эторикоксиб, когнитивно-поведенческая терапия

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/401/391; Парфенов ВА. Причины, диагностика и лечение боли в нижней части спины. Неврология, нейропсихиатрия, психосоматика. 2009;(1):19–22. [Parfenov VA. Low back pain: causes, diagnosis, and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2009;(1):19–22. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2009-17; Подчуфарова ЕВ, Яхно НН. Боль в спине. Москва: ГЭОТАР-Медиа; 2013. 368 с. [Podchufarova EV, Yakhno NN. Bol' v spine [Back pain]. Moscow: GEOTAR-Media; 2013. 368 p.]; Алексеев ВВ, Яхно НН. Основные синдромы поражения нервной системы. В кн.:Болезни нервной системы. Под ред. Н.Н Яхно, Д.Р. Штульмана. В 2 томах. Т. 1. Москва: Медицина; 2001. С. 106–24. [Alekseev VV, Yakhno NN. Main syndromes of defeat of nervous system. In: Bolezni nervnoi sistemy [Diseases of nervous system]. Yakhno NN, Shtul'mana DR, editors. In 2 vol. Moscow: Meditsina; 2001. Vol. 1. P. 106–24.; Подчуфарова ЕВ, Яхно НН. Боли в спине и конечностях. В кн.: Болезни нервной системы. Под ред. Н.Н. Яхно, Д.Р. Штульмана. В 2 томах. Т. 2. Москва: Медицина; 2005. С. 306–31. [Podchufarova EV, Yakhno NN. Back and extremities pains. In: Bolezni nervnoi sistemy [Diseases of nervous system]. Yakhno NN, Shtul'mana DR, editors. In 2 vol. Moscow: Meditsina; 2005. Vol. 2. P. 306–31].; Вахнина НВ. Хроническая пояснично-крестцовая боль: диагностика и лечение. Неврология, нейропсихиатрия, психосоматика. 2010;(3):30–4. [Vakhnina NV. Chronic lumbosacral pain: diagnosis and treatment. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;(3):30–4. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2010-97.; Airaksinen O, Brox JI, Cedraschi C, et al. European guidelines for the management of chronic nonspecific low back pain. Eur Spine J. 2006;15 Suppl 2:S192–300. DOI: http://dx.doi.org/10.1007/s00586-006-1072-1.; Ferrell B, Argoff CE, Epplin J, et al. Pharmacological management of persistent pain in older persons. American geriatrics society panel on the pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331–46. DOI:10.1111/j.1532-5415.2009.02376.x. Epub 2009 Jul 2.; Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability – a randomized, placebo-controlled, 3-month trial. J Pain. 2003;4(6):307–15. DOI: http://dx.doi.org/10.1016/S1526-5900(03)00633-3.; Van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-twoweek, randomized, controlled study. Arthritis Rheum. 2005 Apr;52(4):1205–15. DOI: http://dx.doi.org/10.1002/art.20985.; Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004 May;18(7):790–804. DOI: http://dx.doi.org/10.1096/fj.03-0645rev.; Clark DW, Layton D, Shakir SA. Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Saf.2004;27(7):427–56. DOI: http://dx.doi.org/10.2165/00002018-200427070-00002.; Bhala N, Emberson J, Merhi A, et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769–79. DOI:10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.; Van Hooff ML, Ter Avest W, Horsting PP, et al. A short, intensive cognitive behavioral pain management program reduces health-care use in patients with chronic low back pain: two-year follow-up results of a prospective cohort. Eur Spine J. 2012 Jul;21(7):1257–64. DOI: http://dx.doi.org/10.1007/s00586-011-2091-0.; Poulain C, KernОis S, Rozenberg S, et al. Long-term return to work after a functional restoration program for chronic low-back pain patients: a prospective study. Eur Spine J. 2010 Jul;19(7):1153–61. DOI: http://dx.doi.org/10.1007/s00586-010-1361-6.; Froholdt A, Reikeraas O, Brox JI. No difference in 9-year outcome in CLBP patients randomized to lumbar fusion versus cognitive intervention and exercises. Eur Spine J. 2012 Dec;21(12):2531–8. DOI: http://dx.doi.org/10.1007/s00586-012-2382-0.; Staal JB, Hlobil H, Twisk JW, et al. Graded activity for low back pain in occupational health care: a randomized, controlled trial. Ann Intern Med. 2004;140(2):77-84. DOI: http://dx.doi.org/10.7326/0003-4819-140-2-200401200-00007.; Мелкумова КА. Когнитивно-поведенческая психотерапия при лечении хронической боли. Неврология, нейропсихиатрия, психосоматика. 2010;(1):9-13. [Melkumova KA. Cognitive behavioral psychotherapy in the treatment of chronic pain. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2010;(1):9–13. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2010-63.; Gatchel RG, Rollings KH. Evidence informed management of chronic low back pain with cognitive behavioral therapy. Spine J. 2008;8(1):40–4. DOI:10.1016/j.spinee.2007.10.007.; Sveinsdottir V, Eriksen HR, Reme SE. Assessing the role of cognitive behavioral therapy in the management of chronic nonspecific back pain. J Pain Res. 2012;5:371-80. DOI:10.2147/JPR.S25330. Epub 2012 Oct 11.; Черненко ОА. Лечение болевых скелетно-мышечных поясничных синдромов. Русский медицинский журнал. 2000;8(10):408-10. [Chernenko OA. Treatment of pain skeletal and muscular lumbar syndromes. Russkii meditsinskii zhurnal. 2000;8(10):408–10. (In Russ.)]; Aoki Y, Sugiura S, Nakagawa K, et al. Evaluation of nonspecific low back pain using a new detailed visual analogue scale for patients in motion, standing, and sitting: characterizing nonspecific low back pain in elderly patients. Pain Res Treat. 2012;2012:680496. DOI:10.1155/2012/680496. Epub 2012 Nov 18.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/401
https://doi.org/10.14412/2074-2711-2014-2-81-85

СОВРЕМЕННЫЕ ПРИНЦИПЫ ВЕДЕНИЯ ПАЦИЕНТОВ С ХРОНИЧЕСКОЙ НЕСПЕЦИФИЧЕСКОЙ ЛЮМБАЛГИЕЙ

Συγγραφείς: Суслова, Суслова, Черненко, О.

Θεματικοί όροι: ХРОНИЧЕСКАЯ БОЛЬ В НИЖНЕЙ ЧАСТИ СПИНЫ, ХРОНИЧЕСКАЯ ЛЮМБАЛГИЯ, ЛЕЧЕНИЕ, НЕСТЕРОИДНЫЕ ПРОТИВОВОСПАЛИТЕЛЬНЫЕ ПРЕПАРАТЫ, ЭТОРИКОКСИБ, КОГНИТИВНО-ПОВЕДЕНЧЕСКАЯ ТЕРАПИЯ, МУЛЬТИДИСЦИПЛИНАРНЫЙ ПОДХОД

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/sovremennye-printsipy-vedeniya-patsientov-s-hronicheskoy-nespetsificheskoy-lyumbalgiey
http://cyberleninka.ru/article_covers/15621221.png

Etoricoxib (arcoxia) in rheumatology ; Эторикоксиб (аркоксиа) в ревматологии

Συγγραφείς: Fatima Magomedovna Kudaeva, V G Barskova, Fatima Magomedovna Kudayeva, Ф. М. Кудаева, В. Г. Барскова

Πηγή: Modern Rheumatology Journal; Том 5, № 2 (2011); 61-64 ; Современная ревматология; Том 5, № 2 (2011); 61-64 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2011-2

Θεματικοί όροι: эторикоксиб, rheumatic diseases, etoricoxib, ревматические заболевания

Relation: Patrignani P., Capone M., Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin Pharmacother 2003; 4(2): 265-84. Martina S., Vesta K., Ripley T. Etoricoxib: a highly selective COX-2 inhibitor. Ann Pharmacother 2005; 39(5): 854-62. Brooks P., Kubler P. Etoricoxib for arthritis and pain management. Ther Clin Risk Manag 2006; 2(1): 45-57. Zacher J., Feldman D., Gerli R. et al. A comparison of the therapeutic efficacy and tolerability of Etoricoxib and Diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19(8): 725-36. Wiesenhutter C.W., Boice J.A., Ko A. et al. A comparison of the therapeutic efficacy of Etoricoxib and Ibuprofen in patients with osteoarthritis: randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 470-9. Collantes E., Curtis S.P., Lee K.W. et al. International randomized controlled study of etoricoxib in rheumatoid arthritis. BMC Fam Pract 2002; 3: 10. Van der Heijde D., Baraf H., Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthr Rheum 2005; 52(4): 1205-15. Schumacher H., Boice J., Dahikh D. et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488-92. Pallay R.M., Seger W., Adler J.L. et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol 2004; 33: 257-66. Birbara C.A., Puopolo A.D., Munoz D.R. et al. Treatment of chronic low back pain with etoricoxib, a new cyclooxygenase-2 selective inhibitor: improvement in pain and disability - a randomized, placebo-controlled, 3-month trial. J Pain 2003; 4: 307-15. Boonriong T., Tangtrakulwanich B., Glablay P. et al. Comparing Etoricoxib and Celecoxib for preemptive analgesia for acute postoperative pain in patients undergoing arthroscopic anterior cruciate ligament reconstruction: a randomized controlled trial. BMC Musculoskeletal Dis 2010; 11: 246. Siddiqui A., Sadat-Ali M., Al-Ghamdi A. et al. The effect of etoricoxib premedication on postoperative analgesia requirement in orthopedic and trauma patients. Saudi Med J 2008; 29(7): 966-70.

Διαθεσιμότητα: https://mrj.ima-press.net/mrj/article/view/356
https://doi.org/10.14412/1996-7012-2011-671